Genesis of Squamous Cell Lung Carcinoma. Sequential Changes of Proliferation, DNA Ploidy, and P53 Expression

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 1994 Feb 1

PMID 7906095

Citations 20

Authors

T Hirano

B Franzen

H Kato

Y Ebihara

G Auer

Affiliations

Soon will be listed here.

Abstract

Squamous cell lung carcinomas (SCCs) represent a highly malignant group of tumors, and effective treatment is greatly dependent upon early diagnosis. However, objective diagnosis of atypia is difficult and useful markers need to be defined. In this study, genomic instability, cell proliferation, and cellular accumulation of mutant p53, as reflected by DNA aneuploidy, proliferating cell nuclear antigen, and p53 immunoreactivity, respectively, were evaluated in bronchial squamous metaplasia without atypia (n = 4), bronchial squamous metaplasia with low-grade atypia (n = 12), bronchial squamous metaplasia with high-grade atypia (n = 15), early-stage SCC (n = 15), and advanced-stage SCC (n = 33). Our results suggest that hyperproliferation is an early event followed by DNA aneuploidy, which in turn precedes p53 immunoreactivity in the genesis of SCC. We conclude that routine assessment of proliferating cell nuclear antigen, DNA ploidy, and p53 may be valuable for the early diagnosis of SCC.

Citing Articles

Effects of aneuploidy on cell behaviour and function.

Li R, Zhu J Nat Rev Mol Cell Biol. 2022; 23(4):250-265.

PMID: 34987171 DOI: 10.1038/s41580-021-00436-9.

Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer.

Chen S, Tsuneyama K, Yen M, Lee J, Chen J, Huang S Sci Rep. 2021; 11(1):12033.

PMID: 34103583 PMC: 8187442. DOI: 10.1038/s41598-021-91454-2.

Screening and identification of key biomarkers in lung squamous cell carcinoma by bioinformatics analysis.

Man J, Zhang X, Dong H, Li S, Yu X, Meng L Oncol Lett. 2019; 18(5):5185-5196.

PMID: 31612029 PMC: 6781567. DOI: 10.3892/ol.2019.10873.

Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.

Kita K, Fukuda K, Takahashi H, Tanimoto A, Nishiyama A, Arai S Cancer Sci. 2019; 110(10):3215-3224.

PMID: 31432603 PMC: 6778641. DOI: 10.1111/cas.14171.

DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells.

Teneng I, Picchi M, Leng S, Dagucon C, Ramalingam S, Tellez C DNA Repair (Amst). 2019; 79:1-9.

PMID: 31055244 PMC: 6551272. DOI: 10.1016/j.dnarep.2019.04.006.

References

Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

Iggo R, Gatter K, Bartek J, Lane D, Harris A . Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990; 335(8691):675-9. DOI: 10.1016/0140-6736(90)90801-b. View

Hsu I, Metcalf R, Sun T, Welsh J, Wang N, Harris C . Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991; 350(6317):427-8. DOI: 10.1038/350427a0. View

Sidransky D, von Eschenbach A, Tsai Y, Jones P, Summerhayes I, Marshall F . Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991; 252(5006):706-9. DOI: 10.1126/science.2024123. View

Loeb L . Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991; 51(12):3075-9. View

Levine A, Momand J, Finlay C . The p53 tumour suppressor gene. Nature. 1991; 351(6326):453-6. DOI: 10.1038/351453a0. View

Vahakangas K, Samet J, Metcalf R, Welsh J, BENNETT W, Lane D . Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992; 339(8793):576-80. DOI: 10.1016/0140-6736(92)90866-2. View

Lee J, Lippman S, Hong W, Ro J, Kim S, Lotan R . Determination of biomarkers for intermediate end points in chemoprevention trials. Cancer Res. 1992; 52(9 Suppl):2707s-2710s. View

Lane D . Cancer. p53, guardian of the genome. Nature. 1992; 358(6381):15-6. DOI: 10.1038/358015a0. View

10.

Mazars R, Spinardi L, BENCHEIKH M, Simony-Lafontaine J, Jeanteur P, Theillet C . p53 mutations occur in aggressive breast cancer. Cancer Res. 1992; 52(14):3918-23. View

11.

Gaub J, Auer G, Zetterberg A . Quantitative cytochemical aspects of a combined feulgen-naphthol yellow S staining procedure for the simultaneous determination of nuclear and cytoplasmic proteins and DNA in mammalian cells. Exp Cell Res. 1975; 92(2):323-32. DOI: 10.1016/0014-4827(75)90386-9. View

12.

Auer G, Ono J, NASIELL M, CASPERSSON T, Kato H, Konaka C . Reversibility of bronchial cell atypia. Cancer Res. 1982; 42(10):4241-7. View

13.

NASIELL M, CARLENS E, Auer G, Hayata Y, Kato H, Konaka C . Pathogenesis of bronchial carcinoma, with special reference to morphogenesis and the influence on the bronchial mucosa of 20-methylcholanthrene and cigarette smoking. Recent Results Cancer Res. 1982; 82:53-68. DOI: 10.1007/978-3-642-81768-7_6. View

14.

Kato H, Konaka C, Hayata Y, Ono J, Iimura I, Matsushima Y . Lung cancer histogenesis following in vivo bronchial injections of 20-methylcholanthrene in dogs. Recent Results Cancer Res. 1982; 82:69-86. DOI: 10.1007/978-3-642-81768-7_7. View

15.

Ono J, Auer G, CASPERSSON T, NASIELL M, Saito T, Konaka C . Reversibility of 20-methylcholanthrene-induced bronchial cell atypia in dogs. Cancer. 1984; 54(6):1030-7. DOI: 10.1002/1097-0142(19840915)54:6<1030::aid-cncr2820540617>3.0.co;2-9. View

16.

Levine A . The p53 tumour suppressor gene and product. Cancer Surv. 1992; 12:59-79. View

17.

Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani C, Pastorino U . Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 1992; 52(21):6079-82. View

18.

Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen N . p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene. 1992; 7(10):1989-97. View

19.

Mittal K, Demopoulos R, Goswami S . Proliferating cell nuclear antigen (cyclin) expression in normal and abnormal cervical squamous epithelia. Am J Surg Pathol. 1993; 17(2):117-22. DOI: 10.1097/00000478-199302000-00003. View

20.

Klein N, Vignaud J, Sadmi M, Plenat F, Borelly J, DUPREZ A . Squamous metaplasia expression of proto-oncogenes and P 53 in lung cancer patients. Lab Invest. 1993; 68(1):26-32. View